Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India.
Poviztra is the second brand of its weight loss drug Wegovy that Novo Nordisk will be launching in India. It had launched Wegovy (semaglutide injection 2.4 mg) in the country in June.
Emcure is now exclusive distributor and commercial partner for Poviztra. The collaboration will strengthen the distribution and marketing, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India, the two companies said in a statement. Emcure shares closed 4.89% higher at Rs. 1,427.65 apiece on the BSE.
“We launched Wegovy in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe and effective obesity treatment. This partnership brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s robust marketing and distribution capabilities to improve access to obesity treatment…” said Jay Thyagarajan, Senior V-P, Region APAC of Novo Nordisk.
Emcure CEO and MD Satish Mehta the company’s strong understanding of the country’s diverse geographical landscape and established marketing capabilities would help reaching the products to patients who need it the most.
Published – November 10, 2025 10:50 pm IST
